Latest Insider Transactions at Estee Lauder Companies Inc (EL)
This section provides a real-time view of insider transactions for Estee Lauder Companies Inc (EL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ESTEE LAUDER COMPANIES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ESTEE LAUDER COMPANIES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 08
2021
|
Zinterhofer Aerin Lauder Trust U/A/D 4/24/00 > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
170,000
-6.88%
|
$51,340,000
$302.1 P/Share
|
|
Jun 07
2021
|
Zinterhofer Aerin Lauder Trust U/A/D 4/24/00 > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
675,000
+50.0%
|
-
|
|
Jun 07
2021
|
Irvine O Hockaday Jr Director |
SELL
Open market or private sale
|
Direct |
2,740
-100.0%
|
$827,480
$302.23 P/Share
|
|
Jun 01
2021
|
Fabrizio Freda President and CEO |
SELL
Open market or private sale
|
Direct |
32,209
-29.86%
|
$9,920,372
$308.0 P/Share
|
|
May 27
2021
|
Rose Marie Bravo Director |
SELL
Open market or private sale
|
Direct |
4,234
-100.0%
|
$1,287,136
$304.23 P/Share
|
|
May 27
2021
|
Rose Marie Bravo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,234
+40.52%
|
$707,078
$167.19 P/Share
|
|
May 24
2021
|
Sara E Moss Vice Chairman |
BUY
Bona fide gift
|
Indirect |
5,345
+10.53%
|
-
|
|
May 24
2021
|
Sara E Moss Vice Chairman |
SELL
Bona fide gift
|
Indirect |
5,345
-26.73%
|
-
|
|
May 11
2021
|
Cedric Prouve Group President, International |
SELL
Bona fide gift
|
Direct |
67,800
-28.55%
|
-
|
|
May 11
2021
|
Leonard A. Lauder 2013 Revocable Trust Director |
SELL
Bona fide gift
|
Direct |
150,000
-57.23%
|
-
|
|
May 11
2021
|
Leonard A. Lauder 2013 Revocable Trust Director |
BUY
Bona fide gift
|
Direct |
75,000
+50.0%
|
-
|
|
May 10
2021
|
Lynn Forester Director |
SELL
Open market or private sale
|
Direct |
880
-10.26%
|
$266,640
$303.15 P/Share
|
|
May 10
2021
|
Lynn Forester Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,576
+34.79%
|
$260,832
$57.53 P/Share
|
|
May 07
2021
|
Tracey Thomas Travis EVP & CFO |
SELL
Open market or private sale
|
Direct |
26,792
-46.09%
|
$8,171,560
$305.01 P/Share
|
|
May 07
2021
|
Tracey Thomas Travis EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,792
+31.48%
|
$2,062,984
$77.35 P/Share
|
|
May 07
2021
|
Richard D Parsons Director |
SELL
Open market or private sale
|
Direct |
2,329
-100.0%
|
$703,358
$302.36 P/Share
|
|
May 07
2021
|
Richard D Parsons Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,329
+50.0%
|
$333,047
$143.39 P/Share
|
|
May 07
2021
|
John Demsey Group President |
SELL
Open market or private sale
|
Direct |
1,500
-14.97%
|
$448,500
$299.9 P/Share
|
|
May 05
2021
|
Ronald S Lauder Chairman, Clinique Labs, LLC |
SELL
Open market or private sale
|
Direct |
1,700,000
-100.0%
|
$496,400,000
$292.0 P/Share
|
|
May 04
2021
|
Charlene Barshefsky Director |
SELL
Open market or private sale
|
Indirect |
910
-2.06%
|
$266,630
$293.54 P/Share
|
|
May 04
2021
|
Charlene Barshefsky Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,576
+9.39%
|
$260,832
$57.53 P/Share
|
|
May 04
2021
|
John Demsey Group President |
SELL
Open market or private sale
|
Direct |
1,000
-9.08%
|
$296,000
$296.02 P/Share
|
|
May 04
2021
|
Michael O'Hare EVP-Global Human Resources |
SELL
Open market or private sale
|
Direct |
2,183
-90.84%
|
$641,802
$294.65 P/Share
|
|
May 04
2021
|
Ronald S Lauder Chairman, Clinique Labs, LLC |
BUY
Conversion of derivative security
|
Direct |
1,700,000
+50.0%
|
-
|
|
Apr 09
2021
|
Sara E Moss Vice Chairman |
SELL
Open market or private sale
|
Direct |
12,000
-100.0%
|
$3,600,000
$300.0 P/Share
|
|
Apr 09
2021
|
Sara E Moss Vice Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+50.0%
|
$1,284,000
$107.95 P/Share
|
|
Apr 09
2021
|
Tracey Thomas Travis EVP & CFO |
SELL
Open market or private sale
|
Direct |
22,924
-42.25%
|
$6,877,200
$300.01 P/Share
|
|
Apr 09
2021
|
Tracey Thomas Travis EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,924
+29.7%
|
$1,742,224
$76.23 P/Share
|
|
Mar 09
2021
|
Tracey Thomas Travis EVP & CFO |
SELL
Open market or private sale
|
Direct |
22,924
-42.25%
|
$6,533,340
$285.01 P/Share
|
|
Mar 09
2021
|
Tracey Thomas Travis EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,924
+29.7%
|
$1,742,224
$76.23 P/Share
|
|
Mar 08
2021
|
Lal Family Partners LP > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,000,000
-100.0%
|
$564,000,000
$282.19 P/Share
|
|
Mar 08
2021
|
Lal Family Partners LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,000,000
+50.0%
|
-
|
|
Mar 05
2021
|
Rose Marie Bravo Director |
SELL
Open market or private sale
|
Direct |
3,588
-31.32%
|
$1,036,932
$289.12 P/Share
|
|
Mar 05
2021
|
Rose Marie Bravo Director |
SELL
Open market or private sale
|
Direct |
412
-27.47%
|
$119,892
$291.76 P/Share
|
|
Mar 03
2021
|
Ronald S Foundation Lauder > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
10,000
-3.41%
|
$2,910,000
$291.53 P/Share
|
|
Mar 03
2021
|
Ronald S Lauder Chairman, Clinique Labs, LLC |
SELL
Open market or private sale
|
Direct |
281,629
-24.97%
|
$81,954,039
$291.39 P/Share
|
|
Mar 02
2021
|
Ronald S Lauder Chairman, Clinique Labs, LLC |
SELL
Open market or private sale
|
Direct |
78,371
-76.1%
|
$22,727,590
$290.96 P/Share
|
|
Mar 02
2021
|
Ronald S Foundation Lauder > 10% Shareholder |
BUY
Bona fide gift
|
Direct |
10,000
+11.5%
|
-
|
|
Mar 02
2021
|
Ronald S Lauder Chairman, Clinique Labs, LLC |
SELL
Bona fide gift
|
Direct |
46,000
-5.78%
|
-
|
|
Mar 02
2021
|
Ronald S Lauder Chairman, Clinique Labs, LLC |
BUY
Conversion of derivative security
|
Direct |
406,000
+50.0%
|
-
|
|
Mar 01
2021
|
Cedric Prouve Group President, International |
SELL
Open market or private sale
|
Direct |
14,753
-1.49%
|
$4,337,382
$294.13 P/Share
|
|
Mar 01
2021
|
Cedric Prouve Group President, International |
BUY
Exercise of conversion of derivative security
|
Direct |
14,753
+2.86%
|
$2,478,504
$168.82 P/Share
|
|
Feb 25
2021
|
Leonard A. Lauder 2013 Revocable Trust Director |
SELL
Bona fide gift
|
Direct |
135,000
-55.76%
|
-
|
|
Feb 25
2021
|
Leonard A. Lauder 2013 Revocable Trust Director |
BUY
Bona fide gift
|
Direct |
67,500
+50.0%
|
-
|
|
Feb 25
2021
|
Cedric Prouve Group President, International |
SELL
Open market or private sale
|
Direct |
4,967
-0.68%
|
$1,450,364
$292.8 P/Share
|
|
Feb 25
2021
|
Cedric Prouve Group President, International |
BUY
Exercise of conversion of derivative security
|
Direct |
4,967
+2.01%
|
$685,446
$138.15 P/Share
|
|
Feb 25
2021
|
Sara E Moss Vice Chairman |
SELL
Open market or private sale
|
Direct |
17,576
-85.4%
|
$5,114,616
$291.0 P/Share
|
|
Feb 25
2021
|
Sara E Moss Vice Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
17,576
+50.0%
|
$1,880,632
$107.95 P/Share
|
|
Feb 24
2021
|
Carl P. Haney EVP Research Prod & Innovation |
SELL
Open market or private sale
|
Direct |
8,000
-56.39%
|
$2,360,000
$295.49 P/Share
|
|
Feb 24
2021
|
John Demsey Group President |
SELL
Open market or private sale
|
Direct |
45,895
-14.5%
|
$13,447,235
$293.37 P/Share
|